Privately-held Danish drugmaker LEO Pharma last week revealed that it is now actively searching for new global or territorial partners to deliver promising new compounds for its dermatology-focused pipeline.
After successfully gaining US Food and Drug Administration approval in April for Picato (ingenol mebutate), a novel treatment for solar keratoses (The Pharma Letter January 29), LEO Pharma – Denmark’s third largest pharma company - has initiated a global search for new partners within the dermatology sector.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze